The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer
Official Title: Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial
Study ID: NCT02404506
Brief Summary: Breast cancer is the most frequent malignancy in women, world-wide the leading cause of cancer mortality. One of the strongest risk factors for developing breast cancer is age, with a prevalence approaching 7% in women \>70 years; more than 40% of breast cancer patients are older than 65 years. Although the survival rate has increased in the last years, about one third of patients will relapse with distant metastases. Treatment for patients with metastatic breast cancer is palliative, therefore maintaining or improving quality of life. The use of taxanes and anthracyclines as first line chemotherapy regimen for metastatic breast cancer is widely accepted. Both taxanes and anthracyclines have considerable side effects, especially in elderly patients. Eribulin, a synthetic analogue of a chemotherapeutically active compound derived from the sea sponge Halichondria okadai, acts as an inhibitor of microtubule dynamics. It is registered as palliative chemotherapy in advanced breast cancer after anthracyclines and taxanes. Studies with eribulin treatment have shown similar efficacy compared to anthracyclines and taxanes, but less toxicity. Those studies showed that often the dose of eribulin had to be reduced during treatment due to toxicity without compromising the efficacy of the treatment. The main objective of the trial is to explore the efficacy of a reduced starting dose of eribulin as first-line treatment in elderly metastatic breast cancer patients. The secondary objective of the trial is to investigate the safety of eribulin in those patients. Eribulin mesilate 1.1mg/m2 i.v. will be administered intravenously every 3 weeks on day 1 and day 8 until progressive disease.
Detailed Description: Due to a rising number of elderly patients, fit for chemotherapy, investigating a well-tolerated and effective first line treatment is warranted. In this specific population often there are contra-indications for the use of standard first line drugs like anthracyclines and taxanes due to comorbidities (e.g. cardiac impairment or Peripheral neuropathy). Response rates in first line treatment with taxanes and anthracyclines usually do not exceed 30%. Eribulin has shown a response rate of 29% and a clinical benefit rate (corresponding to the investigators primary endpoint) of 52% in first line, so the investigators expect similar efficacy, but less toxicity. Optimal dose, schedule and tolerability of this drug in the first line setting are unknown in the elderly population. No information on dose modifications in this population is available. Based on the data of eribulin in the first line with higher efficacy in those patients with dose reductions, the SAKK 25/14 trial investigates the reduced starting-dose of eribulin of 1.1mg/m2 for this vulnerable population of elderly patients. Growth factors to maintain a certain dose level of eribulin are not recommended, respecting the international guidelines. SAKK has a tradition in conducting trials in the elderly population, such as SAKK 25/99 in metastatic breast cancer, SAKK 38/08 in aggressive B-cell-Lymphoma, SAKK 41/10 in metastatic colorectal cancer.
Minimum Age: 70 Years
Eligible Ages: OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Kantonsspital Aarau, Aarau, , Switzerland
Kantonsspital Baden, Baden, , Switzerland
Universitaetsspital-Basel, Basel, , Switzerland
Praxis für ambulante Tumortherapie, Basel, , Switzerland
Istituto Oncologico della Svizzera Italiana, Bellinzona, , Switzerland
Klinik Engeried / Oncocare, Bern, , Switzerland
Inselspital, Bern, Bern, , Switzerland
Spitalzentrum Biel, Biel, , Switzerland
Kantonsspital Graubünden, Chur, , Switzerland
Kantonsspital Frauenfeld / Brustzentrum Thurgau, Frauenfeld, , Switzerland
HFR Fribourg - Hôpital cantonal, Fribourg, , Switzerland
Clinique de Genolier, Genolier, , Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland
Clinica Sant'Anna - Oncologia Varini & Calderoni & Christinat, Lugano, , Switzerland
Kantonsspital Luzern, Luzerne, , Switzerland
Onkologie Zentrum Spital Männedorf, Männedorf, , Switzerland
Kantonsspital Olten, Olten, , Switzerland
Rundum Onkologie am Bahnhofpark, Sargans, , Switzerland
Onkologiezentrum Bürgerspital Solothurn, Solothurn, , Switzerland
Onkologiepraxis Dr. med. Isabella Schönenberger, St. Gallen, , Switzerland
Tumorzentrum ZeTUP, St. Gallen, , Switzerland
Kantonsspital - St. Gallen, St. Gallen, , Switzerland
Regionalspital, Thun, , Switzerland
Kantonsspital Winterthur, Winterthur, , Switzerland
Onkozentrum - Klinik im Park, Zurich, , Switzerland
Brust-Zentrum AG Zürich, Zürich, , Switzerland
Name: Ursula Hasler-Strub, MD
Affiliation: Cantonal Hospital of St. Gallen
Role: STUDY_CHAIR